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Summary
Background Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate 
cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage 
design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic 
acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting ﬁ rst-line, long-term hormone 
therapy. Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib 
(arm D) with hormone therapy alone (control arm A).
Methods Eligible patients were men with newly diagnosed or rapidly relapsing prostate cancer who were starting 
long-term hormone therapy for the ﬁ rst time. Hormone therapy was given as standard care in all trial arms, with local 
radiotherapy encouraged for newly diagnosed patients without distant metastasis. Randomisation was done using 
minimisation with a random element across seven stratiﬁ cation factors. Patients randomly allocated to arm D received 
celecoxib 400 mg twice daily, given orally, until 1 year or disease progression (including prostate-speciﬁ c antigen 
[PSA] failure). The intermediate outcome was failure-free survival (FFS) in three activity stages; the primary outcome 
was overall survival in a subsequent eﬃ  cacy stage. Research arms were compared pairwise against the control arm on 
an intention-to-treat basis. Accrual of further patients was discontinued in any research arm showing safety concerns 
or insuﬃ  cient evidence of activity (lack of beneﬁ t) compared with the control arm. The minimum targeted activity at 
the second intermediate activity stage was a hazard ratio (HR) of 0·92. This trial is registered with ClinicalTrials.gov, 
number NCT00268476, and with Current Controlled Trials, number ISRCTN78818544.
Findings 2043 patients were enrolled in the trial from Oct 17, 2005, to Jan 31, 2011, of whom 584 were randomly 
allocated to receive hormone therapy alone (control group; arm A) and 291 to receive hormone therapy plus celecoxib 
(arm D). At the preplanned analysis of the second intermediate activity stage, with 305 FFS events (209 in arm A, 96 in 
arm D), there was no evidence of an advantage for hormone therapy plus celecoxib over hormone therapy alone: HR 
0·94 (95% CI 0·74–1·20). 2-year FFS was 51% (95% CI 46–56) in arm A and 51% (95% CI 43–58) in arm D. There was 
no evidence of diﬀ erences in the incidence of adverse events between groups (events of grade 3 or higher were noted 
at any time in 123 [23%, 95% CI 20–27] patients in arm A and 64 [25%, 19–30] in arm D). The most common grade 
3–5 events adverse eﬀ ects in both groups were endocrine disorders (55 [11%] of patients in arm A vs 19 [7%] in arm D) 
and musculoskeletal disorders (30 [6%] of patients in arm A vs 15 [6%] in arm D). The independent data monitoring 
committee recommended stopping accrual to both celecoxib-containing arms on grounds of lack of beneﬁ t and 
discontinuing celecoxib for patients currently on treatment, which was endorsed by the trial steering committee.
Interpretation Celecoxib 400 mg twice daily for up to 1 year is insuﬃ  ciently active in patients starting hormone 
therapy for high-risk prostate cancer, and we do not recommend its use in this setting. Accrual continues seamlessly 
to the other research arms and follow-up of all arms will continue to assess eﬀ ects on overall survival.
Funding Cancer Research UK, Pﬁ zer, Novartis, Sanoﬁ -Aventis, Medical Research Council (London, UK).
Introduction
Prostate cancer is a major health problem worldwide, 
accounting for nearly a ﬁ fth of all newly diagnosed male 
cancers. In the UK, roughly 35 000 men are diagnosed 
with prostate cancer each year, and in 2008 almost 
10 000 men died from the disease.1 Globally, 913 000 cases 
were diagnosed in 2008.2 The current standard ﬁ rst-line 
treatment for locally advanced or metastatic prostate 
cancer is hormone therapy, achieved either surgically with 
bilateral orchidectomy or medically with luteinising 
hormone releasing hormone (LHRH) agonists or 
antagonists, or oral antiandrogens,3 with additional 
radiotherapy for locally advanced cases.4,5 Hormone 
therapy produces responses in up to 95% of patients, but 
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it is not curative and disease recurs in nearly all patients; 
median time to progression is estimated as 18–24 months, 
driven by metastatic cases,3 and is longer in patients with 
locally advanced disease.4,5 Such disease is referred 
to as hormone-refractory prostate cancer (HRPC), or in-
creasingly as castrate-refractory prostate cancer (CRPC), 
although androgen-deprivation-refractory prostate can cer 
might be a preferable term. In that setting, there is now a 
range of systemic treatments, including further hormonal 
manipulations,6 bisphosphonates,7 cytotoxic chemo-
therapy,8 radionuclides,9 immunotherapy,10 and newer 
hormone therapies.11 The traditional approach is to assess 
new treatments for prostate cancer in castrate-refractory 
disease. An alternative approach is to inves tigate new 
drugs and new approaches to treatment as ﬁ rst-line 
therapy in patients starting hormone therapy. At this 
point, patients are potentially ﬁ tter and better able to 
tolerate treatment, and intervention in the hormone-naive 
setting might have a better and more durable eﬀ ect.
The STAMPEDE trial (Systemic Therapy for Advanced 
or Metastatic Prostate cancer: Evaluation of Drug 
Eﬃ  cacy; Medical Research Council [MRC] PR08) is 
an innovative, multiarm, multistage (MAMS), 
multicentre, randomised controlled trial. We designed 
the trial to assess the eﬀ ects of a bisphosphonate 
(zoledronic acid), a cytotoxic chemotherapy drug 
(docetaxel), and a cyclo-oxygenase-2 (COX-2) inhibitor 
(celecoxib), as single agents or combinations, in patients 
starting hormone therapy for locally advanced or 
metastatic prostate cancer. The trial is designed with 
separate stages focusing on safety, activity, and eﬃ  cacy 
data; a research arm is only allowed to proceed to the 
ﬁ nal stage of recruitment if the study treatment is shown 
to be acceptably safe and suﬃ  ciently active. We refer to 
lack of suﬃ  cient activity as lack of beneﬁ t.
COX-2 is an isoenzyme induced by various mitogens, 
cytokines, and growth factors that are associated with 
a range of processes including inﬂ ammation12 and 
carcinogenesis.13,14 Various case-control studies have 
shown a reduction in risk of prostate cancer associated 
with the use of non-steroidal anti-inﬂ ammatory drugs 
(NSAIDs), which include inhibition of COX-2 among 
their mode of action.15 Pathological studies show that 
COX-2 is upregulated in carcinomas,16 and one study 
suggested that NSAID use might delay progression from 
subclinical to clinical prostate cancer.17 This combination 
of preclinical and epidemiological data justiﬁ ed assess-
ment of a COX-2 inhibitor in the present trial.
The trial development group (including clinical 
researchers, statisticians, trialists, and patient repre-
sentatives) chose to assess the selective COX-2 inhibitor, 
celecoxib, because data suggest that it is better tolerated 
than other NSAIDs, exhibits activity as a cancer-
preventing agent,18 and shows inhibition of angiogenesis 
and induction of apoptosis in human cancer cells 
including prostate cancer,19 particularly at higher doses.20 
This decision was taken after full consideration of the 
risks and beneﬁ ts, in view of reports of potential adverse 
cardiovascular eﬀ ects.21
No safety concerns were raised during the pilot phase 
and the ﬁ rst intermediate activity analysis, and the 
celecoxib arms were permitted to continue accrual. Here, 
we report the results of the second intermediate analysis 
comparing hormone therapy alone with hormone therapy 
plus celecoxib.
Methods
Study design and participants
STAMPEDE uses an adaptive multiarm, multistage 
design.22,23 This seamless phase 2–3 design starts with 
several trial arms and uses an intermediate outcome to 
adaptively focus accrual away from the less encouraging 
research arms, continuing accrual only with the more 
active interventions. The deﬁ nitive primary outcome of 
the STAMPEDE trial is overall survival. The intermediate 
primary outcome is failure-free survival (FFS) deﬁ ned 
as the ﬁ rst of: PSA failure (PSA >4 ng/mL and PSA >50% 
above nadir); local progression; nodal progression; 
progression of existing metastases or development of 
new metastases; or death from prostate cancer. FFS is 
used as a screening method for activity on the 
assumption that any treatment that shows an advantage 
in overall survival will probably show an advantage in 
FFS beforehand, and that a survival advantage is 
unlikely if an advantage in FFS is not seen. Therefore, 
FFS can be used to triage treatments that are unlikely to 
be of suﬃ  cient beneﬁ t. It is not assumed that FFS is a 
surrogate for overall survival; an advantage in FFS 
might not necessarily translate into a survival 
advantage.
The trial is managed by a trial management group 
(TMG) chaired by the chief investigator. Accumulating 
comparative data are reviewed by the independent data 
monitoring committee (IDMC) and recommendations 
are made to the trial steering committee (TSC), which 
includes independent members, who have the ﬁ nal 
responsibility for decision making (eg, on stopping 
arms). The TSC can view limited accumulating 
comparative trial data to take appropriate action.
Patients were recruited from specialist centres with 
the appropriate local and national approvals. The 
eligibility criteria (detailed in the appendix) en-
compassed a range of patients requiring treatment with 
long-term hormone therapy. We postulated that the 
relative eﬀ ect of the research treatments would be the 
same across trial arms, even if the absolute event rate 
diﬀ ered. We included patients with newly diagnosed 
prostate cancer with metastases to bone, node-positive 
disease, or clinically localised disease with high-risk 
features (at least two of the following: T category 3 or 4, 
Gleason sum score 8–10, or PSA ≥40 ng/mL). 
Additionally, men failing previous localised therapy 
were eligible (subject to restrictions on prior hormone 
therapy) if they had a PSA concentration of 4 ng/mL or 
For the STAMPEDE trial 
protocol see http://
stampedetrial.org/
See Online for appendix
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higher and doubling time of less than 6 months, or PSA 
20 ng/mL or higher, or nodal or metastatic relapse.
Patients had to be ﬁ t for any of the trial treatments, 
with adequate haematological, renal, and liver function, 
and have a WHO performance status of 0 or 1. Patients 
with a conﬁ rmed history of severe cardiovascular prob-
lems, active peptic ulceration, gastrointestinal bleeding, 
or inﬂ ammatory bowel disease were excluded. All 
patients provided written informed consent.
Randomisation and masking
Computer-based randomisation was done centrally 
(via telephone) using minimisation with a random 
element of 80% allocation towards minimising arms, 
balancing on minimisation factors of randomising 
centre, metastases, nodal involvement, age at random-
isation, WHO performance status, type of hormone 
therapy, regular aspirin or NSAID use at baseline, and 
planned use of radiotherapy. Patients could be allocated 
to any of the trial arms. This trial is open label; masking 
was considered impracticable because of the requirement 
for intravenous delivery of zoledronic acid and docetaxel. 
Further details on the design and conduct of the trial are 
presented elsewhere.24,25
Procedures
All patients were planned to receive long-term hormone 
therapy for at least 2 years, and were allowed to start long-
term hormone therapy up to 12 weeks before random-
isation. The permitted methods of hormone therapy were 
LHRH analogues (with short-term antiandrogens to 
cover disease ﬂ are when necessary), maximum androgen 
blockade, LHRH antagonists, orchidectomy, or, in 
patients without metastasis, bicalutamide monotherapy 
(150 mg daily); choice of hormone therapy was based on 
clinician and patient preference. Radiotherapy was 
encouraged for men with N0M0 disease (stratifying on 
intent), with a target window of 6–9 months after starting 
hormone therapy, so that radiotherapy could be given at 
the same time in all trial arms and patients would not 
have chemotherapy and radiotherapy concomitantly. 
Patients allocated to celecoxib were planned to receive 
one 400 mg capsule twice daily, taken orally, until 1 year 
or an FFS event.
Patients were followed up every 6 weeks for 6 months, 
then every 12 weeks for 2 years, then every 6 months for 
5 years, and annually thereafter. PSA measurements 
were done at every follow-up; further tests were at 
the discretion of the treating clinician. Nadir PSA was 
considered the lowest value within 6 months on trial. 
Primary 
outcome
Hazard 
ratio
Power One-
sided 
alpha
Critical 
hazard 
ratio
Control 
events
Stage I: activity FFS 0·75 95% 0·500 1·00 114
Stage II: activity FFS 0·75 95% 0·250 0·92 216
Stage III: activity FFS 0·75 95% 0·100 0·89 334
Stage IV: eﬃ  cacy OS 0·75 90% 0·025 ·· 405
FFS=failure-free survival. OS=overall survival.
Table 1: Statistical design parameters according to study stage
Figure 1: Trial proﬁ le
HT=hormone therapy. FFS=failure-free survival. *Two patients were excluded from the activity analysis in arm A because of errors in event dates that were unresolved at the time of this intermediate 
analysis. Both patients reported FFS events before randomisation. †Patients are conservatively excluded from the safety analysis if they have not returned follow-up data or reported a serious adverse 
event; this is expected since accrual was ongoing at the time of analysis and some patients would not have reached their ﬁ rst on-trial assessment point.
Accrual continues
Follow-up ongoing
Accrual continues
Follow-up ongoing
Accrual continues
Follow-up ongoing
Accrual stopped
Follow-up ongoing
Accrual stopped
Follow-up ongoing
Accrual continues
Follow-up ongoing
96 FFS events 
       median FFS=24 months
291 activity analysis (100%)
259 safety analysis (89%)†
291 hormone therapy (100%)
245 celecoxib (84%)
209 FFS events 
         median FFS=27 months
582 activity analysis (100%)*
527 safety analysis (90%)†
584 hormone therapy (100%)
      0 celecoxib (0%)
Intermediate data presented 
in this report
Data remain masked: 
excluded from this report
Data remain masked: 
excluded from this report
Intermediate data presented 
in this report
Data remain masked: 
excluded from this report
Data remain masked: 
excluded from this report
584 arm A (control HT-alone) 293 arm B (HT + zoledronic 
         acid)
292 arm C (HT + docetaxel) 291 arm D (HT + celecoxib) 291 arm F (HT + celecoxib + 
         zoledronic acid)
292 arm E (HT + docetaxel + 
         zoledronic acid)
2043 men starting long-term hormone therapy 
            for prostate cancer randomised
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Toxicities and symptoms were systematically reported at 
each follow-up; serious adverse events and reactions were 
reported according to the National Cancer Institute 
Common Toxicity Criteria.
Statistical analysis
The sample size was calculated using -nstage- and its 
predecessor programs. This program, which is imple-
mented in Stata, is freely available23 and allows for the 
design of multiarm, multistage trials. We assumed, for 
the control arm, median FFS of 2 years and median 
overall survival of between 4 and 5 years, depending on 
patient mix. We targeted a 25% relative reduction in 
events (hazard ratio [HR] 0·75) for both FFS and 
survival; this translates to a 9% absolute improvement 
at the median time. Table 1 shows the trial design 
parameters, which start with a permissive alpha and 
become stricter over time. These parameters were 
chosen to ensure that meaningful amounts of new data 
would be accumulated between intermediate analyses, 
which were triggered when speciﬁ c numbers of events 
had been reported in the control group (table 1). A one-
sided test was chosen because research arms must pass 
an intermediate hurdle to continue accrual. The power 
was set high throughout the stages to avoid excluding 
an active research arm inappropriately. The overall alpha 
and power levels represent the values for each pairwise 
comparison of research arm against the common 
control arm, accounting for intermediate analyses and 
repeated use of the control arm.
The statistical design parameters translate into a 
series of activity hurdles against which each research 
arm is compared at three predeﬁ ned intermediate 
analyses.24 At the end of the second activity stage, 
reported here, the HR cutpoint was 0·924, determined 
with 95% power and a one-sided alpha of 0·25, with 
analyses planned for when roughly 216 FFS events had 
been reported in the control group. It was anticipated 
that research arms with an HR less favourable than the 
cutpoint would be considered as showing insuﬃ  cient 
activity and accrual might therefore be stopped; accrual 
would continue to the remaining trial arms to collect 
further evidence.
There is no single sample size target for STAMPEDE; 
the trial targets a total of 405 deaths in the control arm 
in comparisons with active research arms, but the 
number of patients required to observe these events 
depends on the accrual rate, actual event rate (mix of 
patients joining the trial), and number of research 
arms shown to be insuﬃ  ciently active at the 
intermediate stages. The duration of accrual and 
follow-up are adjusted to obtain this target.24 We 
anticipated that around 2500–4000 patients would join 
STAMPEDE over 6–8 years, with around 1500 patients 
in comparisons of research arms showing encouraging 
evidence at each intermediate analysis. Twice as many 
patients are recruited to the control group as to any of 
the research groups. This is because the control group 
is in every pairwise comparison and the power of these 
comparisons is improved by having more patients in 
this group.
Standard survival analysis methods were used for 
time-to-event data. A log-rank test was used to compare 
event times using the Kaplan-Meier method. Cox’s 
proportional hazards models were used to estimate the 
relative treatment eﬀ ects, adjusting for key stratiﬁ cation 
factors, with relative improvements expressed as HRs; 
HR less than 1·00 favours a research arm. The 
proportional hazards assumption was tested; provision 
was made to report restricted mean survival times and 
to translate the stopping boundaries appropriately in 
the instance of a non-proportional treatment eﬀ ect over 
time.26 All CIs are provided at the 95% level for tradition, 
but a one-sided 75% CI is also included for primary 
comparison of FFS, in line with the trial design. All 
HT only 
(n=584)
HT + 
celecoxib 
(n=291)
WHO performance status
0 448 (77%) 223 (77%)
1 127 (22%) 64 (22%)
2 8 (1%) 4 (1%)
Missing 1 0
Age (years)
Median (IQR) 65 (59–70) 65 (60–71)
Range 41–82 41–80
Missing 0 0
PSA (ng/mL)
Median (IQR) 67 (24–201) 58 (23–175)
Range 1–15 747 2–5000
Missing 0 0
Days from diagnosis
Median (IQR) 75 (51–99) 70 (52–96)
Range 0–3594 1–3359
Missing 45 30
Pain from prostate cancer
Absent 428 (81%) 232 (89%) 
Present 99 (19%) 29 (11%) 
Missing 57 30
T category
T0 4 (1%) 1 (0%)
T1 10 (2%) 6 (2%)
T2 52 (9%) 16 (5%)
T3 376 (64%) 191 (66%)
T4 97 (17%) 52 (18%)
TX 45 (8%) 25 (9%)
N stage
N0 266 (46%) 132 (45%)
N+ 278 (48%) 138 (47%)
NX 40 (7%) 21 (7%)
(Continues in next column)
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patients are included in the analyses on an intention-to-
treat basis.
Toxicities and symptoms were considered together 
from routinely collected toxicity reports and spontan-
eously reported serious adverse event (SAE) datasets. 
Patients who had not returned follow-up (or SAE) data 
were conservatively excluded from the safety dataset 
and assessment of toxicity. The proportions of patients 
with grade 3–5 toxicities were not formally compared. 
Analyses were done with Stata (version 11).
The trial is registered with ClinicalTrials.gov, number 
NCT00268476, and with Current Controlled Trials, 
number ISRCTN78818544.
Role of the funding source
The trial was sponsored by the MRC and conducted by 
the MRC Clinical Trials Unit. MRC employees were 
central to the conduct of the trial and the development of 
this manuscript. Only authors MRS and GJ had access to 
raw data; processed data released by the IDMC and TSC 
were available to all coauthors. Cancer Research UK 
approved the trial design but had no further input. Pﬁ zer, 
Novartis, and Sanoﬁ -Aventis approved the trial design 
and participated in discussions on the progress of the 
trial. Representatives from these industry partners 
were invited to comment on the manuscript but only 
typographic issues were noted. The analyses were driven 
by prespeciﬁ ed criteria and the decision to submit for 
HT only 
(n=584)
HT + 
celecoxib 
(n=291)
(Continued from previous column)
Metastases
None 229 (39%) 115 (40%)
One or more sites 355 (61%) 176 (60%)
Bone metastasis 308 (53%) 151 (52%)
Liver metastasis 8 (1%) 2 (<1%)
Lung metastasis 18 (3%) 5 (2%)
Nodal metastasis 109 (19%) 49 (17%)
Other metastasis 23 (4%) 19 (7%)
Aspirin or NSAID use
No 436 (75%) 218 (75%)
Yes 148 (25%) 73 (25%)
Planned or current HT
LHRH 574 (98%) 286 (98%)
Orchidectomy 3 (<1%) 2 (<1%)
Bicalutamide 7 (1%) 3 (1%)
Missing 39 26
Time from starting HT (days)
Median (IQR) 38 (15–60) 32 (16–53)
Range –34 to 105 –31 to 97
Missing 6 3
Planned antiandrogen use
Short-term antiandrogen 387 (84%) 183 (82%)
Long-term antiandrogen 74 (16%) 41 (18%)
Missing 123 67
Radiotherapy planned
No 439 (75%) 220 (76%)
Yes 145 (25%) 71 (24%)
Participation in QoL study
No 4 (2%) 1 (<1%)
Yes 208 (98%) 103 (99%)
Not invited* 372 187
Smoking status
No 460 (86%) 237 (87%)
Yes 77 (14%) 35 (13%)
Missing on cardiovascular assessment 7 3
Cardiovascular assessment not yet received 40 16
(Continues in next column)
HT only 
(n=584)
HT + 
celecoxib 
(n=291)
(Continued from previous column)
Diabetes
No 494 (91%) 251 (91%)
Yes, type 1 11 (2%) 6 (2%)
Yes, type 2 38 (7%) 18 (7%)
Missing on cardiovascular assessment 1 0
Cardiovascular assessment not yet received 40 16
Myocardial infarction
No 531 (98%) 268 (97%)
Yes, but still ﬁ t for trial 11 (2%) 7 (3%)
Missing on cardiovascular assessment 2 0
Cardiovascular assessment not yet received 40 16
Cerebrovascular disease
No 538 (99%) 272 (99%)
Yes, but still ﬁ t for trial 4 (1%) 3 (1%)
Missing on cardiovascular assessment 2 0
Cardiovascular assessment not yet received 40 16
Congestive heart failure
No 538 (100%) 273 (99%)
Yes, but still ﬁ t for trial 2 (<1%) 2 (1%)
Missing on cardiovascular assessment 4 0
Cardiovascular assessment not yet received 40 16
Angina
No 525 (97%) 264 (96%)
Yes, but still ﬁ t for trial 17 (3%) 10 (4%)
Missing on cardiovascular assessment 2 1
Cardiovascular assessment not yet received 40 16
Hypertension
No 355 (65%) 179 (65%)
Yes, but still ﬁ t for trial 188 (35%) 96 (35%)
Missing on cardiovascular assessment 1 0
Cardiovascular assessment not yet received 40 16
HT=hormone therapy. PSA=prostate-speciﬁ c antigen. NSAID=non-steroidal 
anti-inﬂ ammatory drug. LHRH=luteinising hormone releasing hormone. 
QoL=quality of life. *After Oct 21, 2008, the QoL substudy stopped recruiting new 
patients; around 700 patients were in the trial at that point.  
Table 2: Baseline characteristics
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publication was made by the TMG, following guidance 
from the IDMC and TSC. The corresponding author had 
full access to all of the data and the ﬁ nal responsibility to 
submit for publication.
Results
Data were frozen on Feb 1, 2011, for review by the IDMC 
on March 31, 2011. Between Oct 17, 2005, and Jan 31, 2011, 
STAMPEDE recruited 2043 patients from 85 centres in 
the UK and Switzerland. 584 patients were randomly 
allocated to receive hormone therapy alone and 291 to 
receive hormone therapy plus celecoxib. Figure 1 shows 
the ﬂ ow of patients through the trial; table 2 gives the 
baseline characteristics of patients in this comparison.
In both arms, androgen-deprivation therapy was 
LHRH based in nearly all patients (574 of 584 [98%] in 
the control group and 286 of 291 [98%] in the hormone 
therapy plus celecoxib group), with radiotherapy planned 
for around a quarter of patients. More than one-third of 
patients stopped celecoxib sooner than 1 year after 
randomisation (ﬁ gure 2). The reason for stopping 
celecoxib was known for 107 of these patients: 45 (42%) 
completed protocol treatment, 30 (28%) had disease 
progression, 12 (11%) had excessive toxicity, and 20 (19%) 
stopped for other reasons. Data on radiotherapy are not 
available at this stage.
209 FFS events were observed in the control group and 
96 in the hormone therapy plus celecoxib group. Median 
FFS was 27 months (95% CI 20–39) in the control group, 
with an FFS at 2 years of 51% (95% CI 46–56). In the 
hormone therapy plus celecoxib group, median FFS was 
24 months (95% CI 17–33), with an FFS at 2 years of 
51% (95% CI 43–58).
In the 209 patients in the control group who had an 
FFS event, the ﬁ rst reported event was PSA failure 
in 163 patients (78%), metastases in 33 (16%), local 
progression in ﬁ ve (2%), lymph-node progression in ﬁ ve 
(2%), and prostate-cancer-related death in three (1%). In 
the 96 patients in the hormone therapy plus celecoxib 
group who reported an FFS event, the ﬁ rst event was 
PSA failure in 75 (78%), metastases in 15 (16%), local 
progression in two (2%) and prostate-cancer-related death 
in four (4%).
At this second intermediate analysis, celecoxib showed 
insuﬃ  cient evidence of activity, in terms of FFS, for con-
tinuation of accrual to this comparison: HR 0·94 from 
adjusted Cox model (75% CI upper limit 1·03; 95% CI 
0·74–1·20; ﬁ gure 3). The HR point estimate was less 
favourable than the prespeciﬁ ed activity cutpoint of 0·924. 
Because of the lack of beneﬁ t indicated by this analysis, 
the IDMC recommended discontinuing recruitment to 
both celecoxib-containing groups (hormone therapy plus 
celecoxib [arm D], and hormone therapy plus celecoxib 
plus zoledronic acid [arm F]), and this was endorsed by 
the TSC. Treatment with celecoxib was also discontinued 
in both arms. Treatment with zoledronic acid continues 
in the combination group (arm F).
There is some evidence of non-proportional hazards in 
the data, which is mostly explained by WHO performance 
status (p=0·007); there was no evidence that the hazards 
for the treatment eﬀ ect are non-proportional over time 
(p=0·387). A ﬂ exible parametric model with three degrees 
of freedom allowing for time-varying treatment eﬀ ects 
estimated an HR of 0·96 (95% CI 0·88–1·05). Other 
sensitivity analyses were consistent with the lack of 
additional activity of celecoxib (data not shown). The 
restricted mean FFS time over the ﬁ rst 48 months on 
trial was 26·9 months in the hormone therapy plus 
Figure 3: Kaplan-Meier curve of failure-free survival in arm A (hormone therapy alone) versus arm D (hormone 
therapy plus celecoxib)
HT=hormone therapy. C=celecoxib.
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celecoxib group compared with 26·7 months in the 
control group; the diﬀ erence was 0·3 months (95% CI 
–5·3 to 5·8; p=0·92).
The safety dataset includes 786 patients (90%): 527 in 
the hormone therapy alone group and 259 in the hormone 
therapy plus celecoxib group. Grade 3–5 tox icities were 
reported at any time by 123 (23%; 95% CI 20–27) patients 
in the control group and 64 (25%, 19–30) in the hormone 
therapy plus celecoxib group. Grade 3–5 events were 
mainly endocrine eﬀ ects related to hormone therapy in 
both groups (table 3). There was no evidence of treatment-
related cardiovascular dysfunction.
Activity and safety data for all other trial arms were 
reviewed by the IDMC but were not released for further 
review. These data, including those for the hormone 
therapy plus celecoxib plus zoledronic acid group, remain 
conﬁ dential to the IDMC and will only be available to the 
TSC after future analyses.
Discussion
In the STAMPEDE trial, we are assessing several 
drugs in combination with hormone therapy in patients 
with high-risk localised or metastatic prostate cancer. 
Resources are focused on trial arms most likely to 
show a clinically meaningful survival beneﬁ t by using 
intermediate lack-of-beneﬁ t analyses and stopping 
accrual to arms showing insuﬃ  cient activity or adverse 
safety proﬁ les.
The celecoxib arm continued accrual through the ﬁ rst 
intermediate analysis (target HR 1·00), but accrual was 
stopped after the second intermediate analysis when the 
target HR was more diﬃ  cult to pass, at 0·92. Recruitment 
to the hormone therapy plus celecoxib group was stopped 
with immediate eﬀ ect. Although there were no safety 
concerns raised by the IDMC, there was no evidence of 
beneﬁ t when the totality of the data were taken into 
consideration, and the TSC recommended that treatment 
with celecoxib stop for patients still receiving the drug.
Our premise is that an advantage in overall survival 
should be preceded by an advantage in FFS, so we do 
not anticipate a later beneﬁ t with celecoxib emerging; 
however, this remains to be determined in subsequent 
analysis of overall survival after longer follow-up. In some 
CRPC studies this assumption has not held up, particularly 
studies with the immunotherapy sipuleucel-T, where a 
survival advantage has been shown without a prior beneﬁ t 
in PSA progression.10 The potential mechanisms of action 
of celecoxib are not androgen-linked, so it is reasonable to 
assume that they might not be reﬂ ected in PSA-based 
measures of FFS; on this basis, we continue long-term 
patient follow-up and avoid deﬁ nitive statements relating 
to the overall eﬃ  cacy of COX-2 inhibition and prostate-
cancer survival in this setting.
Recruitment was also stopped to the hormone therapy 
plus celecoxib plus zoledronic acid group; data for this 
arm have not been revealed to avoid inappropriate 
inﬂ uence on recruitment in the other zoledronic acid-
containing arms. These data will subsequently become 
available, giving further information from an additional 
450 patients randomised to receive celecoxib as part of 
treatment. The patients in both celecoxib-containing 
groups remain in the trial and will continue to be followed 
Hormone therapy alone (n=527)* Hormone therapy plus celecoxib (n=259)
Grade 1–2 Grade 3–4 Grade 5 Grade 1–2 Grade 3–4 Grade 5
Cardiac disorder 42 (8%) 7 (1%) 1 (<1%)† 37 (14%) 5 (2%) 0 (0%)
Renal 99 (19%) 9 (2%) 0 (0%) 53 (20%) 2 (<1%) 1 (<1%)
Endocrine disorder 363 (70%) 55 (11%) 0 (0%) 162 (63%) 19 (7%) 0 (0%)
Musculoskeletal 322 (61%) 30 (6%) 0 (0%) 135 (52%) 15 (6%) 0 (0%)
General disorder 301 (58%) 15 (3%) 0 (0%) 137 (53%) 8 (3%) 0 (0%)
Nervous system 118 (23%) 9 (2%) 0 (0%) 52 (20%) 6 (2%) 0 (0%)
Respiratory 113 (22%) 7 (1%) 0 (0%) 64 (25%) 7 (3%) 0 (0%)
Gastrointestinal disorder 238 (46%) 8 (2%) 0 (0%) 131 (51%) 5 (2%) 0 (0%)
Laboratory abnormalities 117 (23%) 9 (2%) 0 (0%) 62 (24%) 4 (2%) 0 (0%)
Hepatic disorder 45 (9%) 8 (2%) 0 (0%) 20 (8%) 5 (2%) 0 (0%)
Skin 118 (23%) 5 (<1%) 0 (0%) 62 (24%) 2 (<1%) 0 (0%)
Blood or bone marrow 24 (5%) 3 (<1%) 0 (0%) 9 (3%) 2 (<1%) 0 (0%)
Blood and lymphatic 89 (17%) 3 (<1%) 0 (0%) 47 (18%) 1 (<1%) 0 (0%)
Psychiatric 143 (28%) 3 (<1%) 0 (0%) 72 (28%) 0 (0%) 0 (0%)
Metabolic and nutritional 53 (10%) 1 (<1%) 0 (0%) 23 (9%) 2 (<1%) 0 (0%)
Allergic reaction 19 (4%) 1 (<1%) 0 (0%) 11 (4%) 1 (<1%) 0 (0%)
Ocular 39 (8%) 1 (<1%) 0 (0%) 16 (6%) 0 (0%) 0 (0%)
Peripheral oedema 64 (12%) 0 (0%) 0 (0%) 31 (12%) 0 (0%) 0 (0%)
*Percentages account for missing data for some of the toxicities for between two and nine patients. †Complication of cardiac intervention.
Table 3: Incidence of adverse eﬀ ects any time after randomisation, by category
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up to provide data on overall survival. Subgroup analyses 
by disease stage were done but not made available for 
reporting. The IDMC charter allows it to make 
recommendations within a subgroup if warranted by the 
data. There would have been limited power for such a 
comparison at this stage.
Celecoxib, a selective COX-2 inhibitor, was selected 
on the basis of preclinical13,14,19 and clinical16–18 data 
suggesting possible utility in prostate cancer (panel). The 
celecoxib dose and treatment duration chosen for the 
trial (400 mg twice daily for 12 months) was based on the 
dose used for prevention of familial polyposis coli20 and 
the need to minimise potential for cardiovascular risk, 
which seems to present with treatment durations longer 
than 12 months.21 The dose and duration were selected 
after a comprehensive literature review followed by joint 
discussion with patient representatives on the TMG, 
emphasising the importance of such collaboration in the 
design and conduct of clinical trials.
External clinical trial data that have emerged since the 
launch of STAMPEDE have been equivocal as to the value 
of COX-2 inhibitors in prostate27,28 and colorectal29,30 
cancers. So far, published trials have not supported the 
use of COX-2 inhibitors unequivocally in any established 
cancer type; our trial adds further evidence of their 
limited clinical utility in established tumours. We do note 
positive ﬁ ndings for chemoprevention of non-melanoma 
skin cancer in patients with actinic keratoses.31 Several 
trials of celecoxib in other types of established tumours 
continue to recruit patients, including large trials in 
colon (eg, CALGB-80702 [NCT01150045]), bladder (eg, 
BOXIT [ISRCTN84681538]), and breast cancer (eg, 
REACT [ISRCTN48254013]).
We cannot identify at this stage why a drug with a sound 
pretrial rationale would show no evidence of activity in a 
large-scale trial, but there are several possibilities to 
consider. First, there could be lack of expression of the 
target molecule COX-2, which we could retrospectively 
assess by collecting tissue blocks and studying COX-2 
expression. Second, there might be a lack of on-target 
activity; celecoxib was chosen because of documented 
activity in the setting of familial polyposis coli,20 thus it 
seems reasonable to assume that the drug dose and 
delivery are within the necessary therapeutic range. Third, 
the dose or duration of exposure of celecoxib, or both, 
may have been inadequate. The initial planned duration 
of therapy was 2 years, but in view of the excess 
cardiovascular problems reported with rofecoxib29 just 
before accrual to STAMPEDE, a shorter duration was 
selected. Even if the duration was too short for optimum 
eﬀ ect, we would still expect some eﬀ ect, particularly with 
a median time to progression of around 2 years.
A key strength of STAMPEDE is that several thera-
peutic combinations are tested synchronously, thereby 
shortening the time to assess eﬃ  cacy and toxicity in new 
drug combinations in hormone-naive patients under-
going hormone therapy. A further strength is that 
recruitment is broadly based, incorporating more than 
100 centres in two countries. The entry criteria were 
intended to deﬁ ne a population with a poor prognosis, 
requiring long-term hormone therapy, and to test the 
hypothesis that interventions at the point of ﬁ rst 
hormone manipulation improve long-term outcome. 
The trial is predicated on the notion that high-risk 
prostate cancer includes a range of patients, from those 
with localised disease and poor prognostic characteristics 
(based on T category, PSA, and Gleason score) to those 
presenting with metastatic disease, and that current 
therapies have limited long-term eﬃ  cacy in many cases. 
The original statistical design therefore assumed a 
median FFS time of around 2 years; this estimation has 
been validated by the data presented here. Median overall 
survival was assumed to be twice the median FFS, 
although there have been too few deaths to estimate this 
accurately. It seems likely that median survival will be 
higher than originally anticipated, which might be partly 
related to new, active therapies that patients can receive 
after their ﬁ rst trial FFS event. These therapies include 
docetaxel,32,33 which has entered standard practice for 
treatment of later stages of prostate cancer since the trial 
was launched. Further agents are emerging, including 
abiraterone,34 cabazitaxel,35 sipuleucel-T,10 radium-223,36 
and MDV3100.37,38 With the recent demonstration of a 
Panel: Research in context
Systematic review
At the time of trial design, there was substantial 
epidemiological, laboratory, and clinical evidence that COX-2 
has a role in development and progression of a range of 
cancers, including prostate cancer. Celecoxib was chosen for 
assessment in hormone-sensitive prostate cancer based on 
in-vitro evidence of activity and data in other cancers, 
particularly familial polyposis coli, where it has a role in 
prevention of progression from polyp to cancer. We assessed 
a range of drugs with COX-2-inhibitory properties and 
selected celecoxib based on the data in familial polyposis coli 
and its safety proﬁ le in large-scale trials of other diseases. 
Data from trials of celecoxib in established cancers have been 
tracked through the registers (including alerts and 
ClinicalTrials.gov), and lead investigators have been 
contacted for information each time reviews are updated but 
registers do not include recent data.
Interpretation
At the second preplanned intermediate analysis, we have 
shown that celecoxib given at 400 mg twice daily for 1 year is 
insuﬃ  ciently active in high-risk, hormone-sensitive prostate 
cancer to signiﬁ cantly aﬀ ect failure-free survival. Other trials 
in prostate cancer (and other cancer types) have not 
supported the use of COX-2 inhibitors unequivocally in any 
setting, and our trial adds further evidence of the limited 
clinical utility of these drugs in established, advanced cancer. 
We do not recommend their use in these patients.
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survival beneﬁ t with radical radiotherapy in patients 
with locally advanced disease,4,5 we anticipate further 
improve ments in FFS and overall survival; indeed, the 
trial was amended in November, 2011, to mandate the 
use of radiotherapy in newly diagnosed N0M0 disease 
following these results.5 The accumulating event rate is 
monitored as part of trial oversight processes.
The remaining trial arms continue to recruit new 
patients and their data remain masked. Researchers might 
infer that there is at least some evidence of improved FFS 
in these arms, but such evidence is not suﬃ  cient to stop 
or change the trial. A further change to the trial occurred 
in November, 2011, with the intro duction of hormone 
therapy plus abiraterone as a new research arm. Patients 
in the new arm will only be compared with those 
randomised contemporaneously to the control group. The 
trial can adaptively introduce further research arms and 
stop early those arms showing a lack of beneﬁ t.24 Further 
research arms are likely to be introduced into the trial. The 
practical issues in handling the early stopping of the 
celecoxib-containing arms and the addition of further 
research arms will be discussed in a separate paper. In 
conclusion, we have shown that celecoxib given 400 mg 
twice daily for 1 year is insuﬃ  ciently active for men 
starting long-term therapy for high-risk prostate cancer, 
and we do not recommend its use in this setting.
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